Large patient database 

As a clinical study center, Profil understands that a diabetes patient database must be extensive and kept up to date. Rapid enrollment or appropriate patients and healthy subjects is key to the successful and timely completion of clinical trials.

To ensure in-time recruitment, Profil has developed a database of more than 26,000 patients with type 1 and type 2 diabetes and obese and lean healthy subjects.

To meet specific trial requirements, this database can be filtered for major in- and exclusion criteria including but not limited to medical history, laboratory data and concomitant medication (both ingredients and substance classes as coded by the WHO Drug Dictionary). A dedicated in-house database team of three and ten recruitment coordinators remain in close contact with potential study subjects to ensure that the database is always up to date.

Very low drop-out rates

Honoring timelines is about more than just finding study subjects quickly. As the average drop-out rates of all clinical trials is about 30%, many studies are delayed unnecessarily. At Profil, we achieve extremely low average drop-out rates of 7.5% (among randomized subjects in the years 2014-2018), which helps us keep cost low, lets us create more reliable study timelines and ultimately get you the results you need faster.

Facts and Figures

  • Database with > 26,000 active entries (as of November 2022)

    > 11,000 with type 2 diabetes

    > 5,700 with type 1 diabetes

    > 9,600 healthy subjects including defined as obese

  • Records include medical history, lab data, BMI and medication (acc. to WHO Drug Dictionary)

  • Ethnic groups: Caucasians, Japanese

  • Average drop-out rates of only 7.5%

Test our database

Do you already have a study outline? Then test if we can recruit your study.

Check Study

Dr. Lars Bochmann

Our expert

Dr. Lars Bochmann

Director Marketing & Business Development



"Profil has excellent subject recruitment capabilities. The screening system makes it very efficient."

Dr. Chun Shen, CEO, Genova